AstraZeneca PLC (AZN)vsTaseko Mines Ltd (TGB)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
TGB
Taseko Mines Ltd
$6.20
+4.03%
BASIC MATERIALS · Cap: $2.26B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8629% more annual revenue ($58.74B vs $672.90M). AZN leads profitability with a 17.4% profit margin vs -4.5%. TGB appears more attractively valued with a PEG of 0.33. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
TGB
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Intrinsic value data unavailable for TGB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Revenue surging 45.3% year-over-year
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
ROE of -4.7% — below average capital efficiency
Earnings declined 45.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TGB
The strongest argument for TGB centers on PEG Ratio, Revenue Growth. Revenue growth of 45.3% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : TGB
The primary concerns for TGB are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a value stock while TGB is a hypergrowth play — different risk/reward profiles.
TGB carries more volatility with a beta of 1.89 — expect wider price swings.
TGB is growing revenue faster at 45.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (66/100 vs 46/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Taseko Mines Ltd
BASIC MATERIALS · COPPER · USA
Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?